[On the existence of a myeloproliferative factor in patients with a myeloproliferative syndrome (author's transl)].
Serum of patients suffering from a chronic myeloproliferative disorder (polycythaemia, era, osteomyelofibrosis, chronic myeloid leukaemia) and serum of lethally irradiated rats injected before application of a single doses of erythropoietin did not enhance the effect of erythropoietin -- measured with the iron incorporation rate of polycythemic mice. The rationale for these experiments is to try to find a "myeloproliferative factor", which augments the number of stem cells as described in sera of patients with polycythaemia vera, osteomyelofibrosis, and lethally irradiated mice.
D000328:Adult; D000368:Aged; D004357:Drug Synergism; D004921:Erythropoietin / Q000097:blood / Q000494:pharmacology; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood*; D011087:Polycythemia Vera / Q000097:blood; D055728:Primary Myelofibrosis / Q000097:blood
D004921:Erythropoietin
Zur Frage der Existenz eines myeloproliferativen Faktors bei Patienten mit myeloproliferativem Syndrom.